Thermo Fisher Scientific (NYSE:TMO) Releases FY 2026 Earnings Guidance

Thermo Fisher Scientific (NYSE:TMO) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 24.930-25.330 for the period, compared to the consensus estimate of 24.850. The company issued revenue guidance of $47.4 billion-$48.1 billion, compared to the consensus revenue estimate of $47.8 billion.

Wall Street Analyst Weigh In

TMO has been the subject of a number of analyst reports. Morgan Stanley reaffirmed an “overweight” rating and issued a $620.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Wells Fargo & Company reduced their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Wolfe Research assumed coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target on the stock. Sanford C. Bernstein began coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective for the company. Finally, DZ Bank began coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a “buy” rating and a $610.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $602.14.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $526.19 on Thursday. The firm has a fifty day moving average price of $488.92 and a two-hundred day moving average price of $513.21. The company has a market cap of $195.54 billion, a PE ratio of 28.93, a price-to-earnings-growth ratio of 2.32 and a beta of 0.87. Thermo Fisher Scientific has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period in the previous year, the business earned $4.28 EPS. The firm’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts expect that Thermo Fisher Scientific will post 24.84 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by company insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. J. Stern & Co. LLP grew its stake in Thermo Fisher Scientific by 58,006.4% during the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after buying an additional 31,455,105 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Thermo Fisher Scientific by 19.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,701,353 shares of the medical research company’s stock worth $4,462,550,000 after acquiring an additional 1,230,872 shares during the last quarter. Bank of America Corp DE increased its holdings in Thermo Fisher Scientific by 11.0% during the 4th quarter. Bank of America Corp DE now owns 5,945,838 shares of the medical research company’s stock valued at $3,445,316,000 after purchasing an additional 588,239 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Thermo Fisher Scientific by 28.5% in the fourth quarter. Wellington Management Group LLP now owns 3,468,240 shares of the medical research company’s stock valued at $2,009,672,000 after buying an additional 768,780 shares during the last quarter. Finally, Unisphere Establishment grew its holdings in Thermo Fisher Scientific by 5.6% during the 2nd quarter. Unisphere Establishment now owns 2,060,000 shares of the medical research company’s stock worth $835,248,000 after acquiring an additional 110,000 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.